Cargando…

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS‐mutated ovarian cancer cells with high AXL expression

KRAS mutation is frequently seen in a subtype of ovarian cancer categorized as type 1. The KRAS‐MAPK pathway, which is closely involved in type 1 cancer progression, is under the regulation of receptor tyrosine kinases (RTKs). AXL, one of the RTKs, has been reported to be overexpressed in ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Umemura, Shiori, Sowa, Yoshihiro, Iizumi, Yosuke, Kitawaki, Jo, Sakai, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293078/
https://www.ncbi.nlm.nih.gov/pubmed/32291856
http://dx.doi.org/10.1111/cas.14414